Corcept Therapeutics Incorporated (CORT)
Debt-to-equity ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 679,589 | 506,705 | 501,842 | 375,806 | 523,338 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $679,589K
= 0.00
Corcept Therapeutics Incorporated has consistently maintained a debt-to-equity ratio of 0.00 over the five-year period from December 31, 2020, to December 31, 2024. This indicates that the company has not relied on debt financing to fund its operations and growth, as its total debt is either non-existent or significantly lower than its equity. A debt-to-equity ratio of 0.00 reflects a strong financial position and suggests that the company has a low level of financial risk associated with debt. Overall, Corcept Therapeutics' financial structure appears to be conservative and well-managed, with a minimal dependence on external debt to support its operations.
Peer comparison
Dec 31, 2024